ISLET Act

The ISLET Act amends federal regulations to allow the use of human cadaveric islets for transplantation without classifying them as drugs or biological products. This change directly affects patients with diabetes who may receive islet cell transplants and the healthcare providers who administer these procedures. The bill requires the Secretary of Health and Human Services to update existing regulations within one year and submit a progress report to Congress within six months. By removing islets from drug and biological product categories, the legislation aims to streamline regulatory oversight for this specific type of medical treatment.